A new microbial-based platform for the production of high-quality plasmid DNA vaccines and therapeutics has been launched by Lonza.
The pDNA platform consists of three harmonised processes; fermentation, primary recovery, and purification. It begins with a unique, fed batch, high cell density fermentation process compatible with multiple Escherichia coli (E. coli) host organisms, followed by noble primary recovery process performed under low shear conditions.
A unique, two column purification platform based on the differential power of hydrophobic interaction chromatography has also been adopted. By using only two column steps, the purification process becomes far more efficient due to an elimination of host and product derived contaminants, while maintaining high product yields.
Edwin Davies, head of microbial research and development services, commented on the new technology, saying: "We are pleased to expand our microbial offering with a complete pDNA service platform for this growing market. This innovative development platform offers the versatility of multiple host organisms in conjunction with the flexibility of optional on-site strain development services."
Posted by Neil Clark